# US 2012/0252837 A1 · Bicyclic derivatives of azabicyclic carboxamides, preparation thereof and therapeutic use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252837 A1
- Document ID: US20120252837A1
- Status: Published application
- Kind: A1
- Application number: 13/466,629
- Filed: 2012-05-08
- Published: 2012-10-04
- Earliest claimed: 2008-01-22
- Assignees: Sanofi
- Inventors: Laurent Dubois; Yannick Evanno; Catherine Gille; André Malanda
- Web page: https://patentgrep.com/patent/US20120252837A1

## CPC

- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 27/02: Ophthalmic agents
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure relates to compounds of formula (I): wherein X1, X2, X3, X4, Y, n, A, and W are as defined in the disclosure, or a salt thereof, or a hydrate or solvate thereof, and to processes for the preparation of these compounds and the therapeutic use thereof.

## Claims

### Claim 1

A compound corresponding to formula (I):
wherein:
X1, X2, X3 and X4 represent, independently of each other, a nitrogen atom or a group C—R1;
wherein at least one from among X1, X2, X3 and X4 represents a nitrogen atom, the others correspond to a group C—R1;
W represents an oxygen or sulfur atom;
n is equal to 0, 1, 2 or 3;
Y represents an aryl or a heteroaryl optionally substituted with one or more groups chosen from a halogen atom, a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, hydroxyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C6-alkylene-O—, C1-C6-fluoroalkoxy, cyano, C(O)NR4R5, nitro, NR4R5, thiol, —S(O)—C1-C6-alkyl, —S(O)2—C1-C6-alkyl, SO2NR4R5, NR6C(O)R7, NR6SO2R8, C(O)NR4R5, OC(O)NR4R5, —Si—(C1-C6-alkyl)3, —SF5, aryl-C1-C5-alkylene or aryl, heteroaryl-C1-C5-alkylene or heteroaryl; the groups C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C6-alkylene-O— being optionally substituted with a hydroxyl group, C1-C6-alkoxy or NR4R5, the aryl and heteroaryl groups being optionally substituted with one or more substituents R9, which may be identical to or different from each other;
A represents the group of formula:
Z1, Z2, Z3 and Z4 represent, independently of each other, a nitrogen atom, a carbon atom or a group C—R2,
at least one from among Z1, Z2, Z3 and Z4 corresponding to a nitrogen atom and one from among Z1, Z2, Z3 and Z4, corresponding to a carbon atom, being bonded to the nitrogen atom of the amide or of the thioamide of formula (I);
Ra and Rb form, together with the carbon atoms that bear them,
either a partially unsaturated cycloalkyl, or an aryl;
or a heterocycle, or a heteroaryl, which is 5- to 7-membered, comprising from 1 to 3 heteroatoms chosen from O, S and N;
wherein when Ra and Rb together form, with the carbon atoms that bear them, a 5-membered ring, this ring comprising a nitrogen atom and carbon atoms, this ring being partially saturated or unsaturated, is excluded;
the partially unsaturated cycloalkyl, the aryl, the heterocycle or the heteroaryl are optionally substituted with one or more substituents R3;
R1 is chosen from a hydrogen atom, a halogen atom, C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, aryloxy-C1-C6-alkyl, heteroaryloxy-C1-C6-alkyl, aryl-C1-C3-alkylenoxy-C1-C6-alkyl, heteroaryl-C1-C3-alkylenoxy-C1-C6-alkyl, arylthio-C1-C6-alkyl, heteroarylthio-C1-C6-alkyl, aryl-C1-C3-alkylene-thio-C1-C6-alkyl, heteroaryl-C1-C3-alkylene-thio-C1-C6-alkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-fluoroalkoxy, cyano, C(O)NR4R5, nitro, NR4R5, C1-C6-thioalkyl, C3-C7-cycloalkylthio, C3-C7-cycloalkyl-C1-C3-alkylene-thio, —S(O)—C1-C6-alkyl, —S(O)—C3-C7-cycloalkyl, —S(O)—C1-C3-alkylene-C3-C7-cycloalkyl, C1-C6-alkyl-S(O)2—, C1-C6-fluoroalkyl-S(O)2—, C3-C7-cycloalkyl-S(O)2—, C3-C7-cycloalkyl-C1-C3-alkylene-S(O)2—, SO2NR4R5, —Si—(C1-C6-alkyl)3, —SF5, NR6C(O)R7, NR6SO2R8, C(O)NR4R5, OC(O)NR4R5, aryl, heteroaryl, aryl-C1-C5-alkylene, heteroaryl-C1-C5-alkylene, aryloxy, arylthio, heteroaryloxy or heteroarylthio; the heteroaryl or aryl groups being optionally substituted with one or more substituents R9, which may be identical to or different from each other;
R2 represents a hydrogen atom, a halogen atom or a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylene-O—, hydroxyl, thiol or C1-C6-fluoroalkoxy;
R3 represents, when it is borne by a carbon atom, a hydrogen atom or a hydroxyl, thiol, C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-alkoxy-C1-C3-alkylene, C3-C7-cycloalkyloxy-C1-C3-alkylene, C3-C7-cycloalkyl-C1-C3-alkylenoxy-C1-C3-alkylene, C(O)NR4R5, C(O)O—C1-C6-alkyl, CO2H, oxo or thio group; the groups C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-alkoxy-C1-C3-alkylene, C3-C7-cycloalkyloxy-C1-C3-alkylene, C3-C7-cycloalkyl-C1-C3-alkylenoxy-C1-C3-alkylene are optionally substituted with a hydroxyl group, C1-C6-alkoxy, —OC(O)—C1-C6-alkyl or NR4R5;
or
R3 represents, when it is borne by a nitrogen atom, a hydrogen atom or a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, aryl-C(O)—, C1-C6-alkyl-C(O)—, C3-C7-cycloalkyl-C(O)—, C3-C7-cycloalkyl-C1-C3-alkylene-C(O)—, C1-C6-fluoroalkyl-C(O)—, aryl-S(O), C1-C6-alkyl-S(O)—, C1-C6-fluoroalkyl-S(O)—, aryl-S(O)2—, C1-C6-alkyl-S(O)2—; C1-C6-fluoroalkyl-S(O)2—, C3-C7-cycloalkyl-S(O)2—, C3-C7-cycloalkyl-C1-C3-alkylene-S(O)2—, C1-C6-alkyl-O—C(O)—, aryl-C1-C3-alkyl-O—C(O)—, C3-C7-cycloalkyl-O—C(O)—, C3-C7-cycloalkyl-C1-C3-alkylene-O—C(O)—, C1-C6-fluoroalkyl-O—C(O), aryl-O—C(O)—, heteroaryl-O—C(O)—, heteroaryl or aryl; the heteroaryl and aryl groups being optionally substituted with one or more substituents R9, which may be identical to or different from each other; the groups C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene and C1-C6-fluoroalkyl are optionally substituted with a hydroxyl group, C1-C6-alkoxy or NR4R5;
R4 and R5, represent, independently of each other, a hydrogen atom or a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, aryl-C1-C5-alkylene or aryl, or R4 and R5 together form, with the nitrogen atom that bears them, an azetidine, pyrrolidine, piperidine, azepine, morpholine, thiomorpholine, piperazine or homopiperazine group; the group NR4R5 being optionally substituted with a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, aryl-C1-C6-alkylene, aryl, heteroaryl, aryl-S(O)2—, C1-C6-alkyl-S(O)2—, C1-C6-fluoroalkyl-S(O)2, C3-C7-cycloalkyl-S(O)2—, C3-C7-cycloalkyl-C1-C3-alkylene-S(O)2—, aryl-C(O)—, C1-C6-alkyl-C(O)—, C3-C7-cycloalkyl-C(O)—, C3-C7-cycloalkyl-C1-C3-alkylene-C(O)—, C1-C6-fluoroalkyl-C(O)—, hydroxyl, C1-C6-alkyloxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-fluoroalkyl, aryloxy-C1-C6-alkylene, aryloxy, heteroaryloxy-C1-C6-alkylene or heteroaryloxy;
R6 and R7 represent, independently of each other, a hydrogen atom or a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, aryl-C1-C6-alkylene or aryl; the aryl group being optionally substituted with one or more substituents chosen from a halogen atom and a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-fluoroalkoxy, nitro or cyano;
or R6 and R7 together form a 4- to 7-membered lactam comprising the nitrogen atom and the C(O) group that bear them;
R8 represents a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, aryl-C1-C6-alkylene or aryl; the aryl group being optionally substituted with one or more substituents chosen from a halogen atom, a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, C1-C6-fluoroalkoxy, nitro or cyano;
or R6 and R8 together form a 4- to 7-membered sultam comprising the nitrogen atom and the S(O)2 group that bear them;
R9 represents a halogen atom, a group C1-C6-alkyl, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C1-C3-alkylene, C1-C6-fluoroalkyl, C1-C6-alkoxy, C3-C7-cycloalkyloxy, C3-C7-cycloalkyl-C1-C3-alkylenoxy, or C1-C6-fluoroalkoxy; these groups being optionally substituted with a group OH, C1-C6-alkoxy or NR4R5; or alternatively R9 represents a nitro group, cyano or NR4R5;
the sulfur atom(s) of the compound of general formula (I) optionally being in oxidized form;
the nitrogen atom(s) of the compound of general formula (I) optionally being in oxidized form;
or an acid-addition salt thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
X1, X2, X3 represent a group C—R1; X4 represents a nitrogen atom; and
R1 is as defined in formula (I) according to claim 1;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 4 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
R1 is chosen from a hydrogen atom, a halogen atom and a group C1-C6-fluoroalkyl or —Si(C1-C6-alkyl)3;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 5 (depends on 1)

The compound of formula (I) according to claim 1, wherein n is equal to 1;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 6 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
Y represents a phenyl, optionally substituted with one or more groups chosen from a halogen atom and a group C1-C6-alkyl or C1-C6-fluoroalkyl;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 7 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
W represents an oxygen atom;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 8 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
A represents the group of formula:
wherein A is chosen from the groups:
these groups being optionally substituted with R2 and R3 as defined in formula (I) of claim 1;
R2 represents a hydrogen atom;
R3 represents, when it is borne by a carbon atom, a hydrogen atom or a hydroxyl, C1-C6-alkyl or oxo group; the C1-C6-alkyl group is optionally substituted with a hydroxyl or —OC(O)—C1-C6-alkyl group;
or
R3 represents, when it is borne by a nitrogen atom, a hydrogen atom or a group C1-C6-alkyl;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 9 (depends on 1)

The compound of formula (I) according to claim 1, wherein:
X1, X2 and X3 represent a group C—R1; X4 represents a nitrogen atom;
R1 is chosen from a hydrogen atom, a halogen atom and a group C1-C6-fluoroalkyl or —Si—(C1-C6-alkyl)3;
n is equal to 1;
Y represents an aryl or a heteroaryl optionally substituted with one or more groups chosen from a halogen atom and a group C1-C6-alkyl or C1-C6-fluoroalkyl;
W represents an oxygen atom;
A represents the group of formula:
wherein A is chosen from the groups:
these groups being optionally substituted with R2 and R3 as defined in formula (I) of claim 1;
R2 represents a hydrogen atom;
R3 represents, when it is borne by a carbon atom, a hydrogen atom or a hydroxyl, C1-C6-alkyl or oxo group; the C1-C6-alkyl group is optionally substituted with a hydroxyl or —OC(O)—C1-C6-alkyl group;
or
R3 represents, when it is borne by a nitrogen atom, a hydrogen atom or a group C1-C6-alkyl;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 10 (depends on 1)

The compound of formula (I) according to claim 1, selected from the group consisting of:
N-(2,3-Dimethyl-3H-imidazo[4,5-b]pyrid-6-yl)-5-trifluoromethyl-1-[(3-fluorophenyl)methyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;
N-(2-Hydroxymethylthiazolo[5,4-b]pyrid-6-yl)-5-trifluoromethyl-1-[(thiazol-2-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;
N-(2-Hydroxymethylthiazolo[5,4-b]pyrid-6-yl)-5-trifluoromethyl-1-[(pyrid-4-yl)methyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;
N-(2-Hydroxymethylthiazolo[5,4-b]pyrid-6-yl)-5-trifluoromethyl-1-[[(3-trifluoromethyl)-phenyl]methyl]-1H-pyrrolo[2,3-b]pyridine-2-carboxamide;
or an acid-addition salt thereof, or a hydrate or solvate thereof.

### Claim 11

(canceled)

### Claim 12 (depends on 1)

A process for preparing a compound of formula (II):
wherein X1, X2, X3, X4, n, Y and W are as defined in formula (I) according to claim 1, one from among X1, X2, X3 and X4 corresponding to a group C—R1 in which R1 represents a group —Si—(C1-C6-alkyl)3 as defined in the general formula (I) according to claim 1 and B represents a group C1-C6-alkoxyl;
said process comprising reacting a compound of general formula (VI):
wherein X1, X2, X3, X4 and W are as defined in formula (I) according to claim 1 and B represents a group C1-C6-alkoxyl,
with a compound of general formula (VIII):
wherein Y and n are as defined in the general formula (I) according to claim 1; and
when n is equal to 1, 2 or 3, with a reagent of general formula (VIII) in which LG represents a leaving group, in the presence of a base in a polar solvent;
when n is equal to 1, 2 or 3, with a reagent of general formula (VIII) in which LG represents a hydroxyl group, in the presence of a phosphine and diethyl azodicarboxylate in a solvent; or
alternatively in the presence of a phosphine supported on a resin and diisopropyl azodicarboxylate in solution in a solvent; or
when n is equal to 0, with a reagent of general formula (VIII) in which LG represents a leaving group, under an inert atmosphere in basic medium, in the presence of a copper salt in an organic solvent.

### Claim 13

A compound of formula (IIa), (IIb), (IIc), (IId), (IIe), (IIf), (IIg) or (IIh):

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate of said compound, in combination with at least one pharmaceutically acceptable excipient.

### Claim 15 (depends on 3)

A pharmaceutical composition comprising a compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate of said compound, in combination with at least one pharmaceutically acceptable excipient.

### Claim 16 (depends on 3)

A pharmaceutical composition comprising a compound of formula (I) according to claim 3, or a pharmaceutically acceptable salt, hydrate or solvate of said compound, in combination with at least one pharmaceutically acceptable excipient.

### Claim 17 (depends on 4)

A pharmaceutical composition comprising a compound of formula (I) according to claim 4, or a pharmaceutically acceptable salt, hydrate or solvate of said compound, in combination with at least one pharmaceutically acceptable excipient.

### Claim 18 (depends on 10)

A pharmaceutical composition comprising a compound of formula (I) according to claim 10, or a pharmaceutically acceptable salt, hydrate or solvate of said compound, in combination with at least one pharmaceutically acceptable excipient.

### Claim 19 (depends on 1)

A method of treating or preventing a pathology in which receptors of TRPV1 type are involved comprising administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate of said compound.

### Claim 20 (depends on 1)

A method of treating or preventing a pathology selected from pain, inflammation, metabolic disorders, urological disorders, gynaecological disorders, gastrointestinal disorders, respiratory disorders, psoriasis, pruritus, dermal, ocular or mucous irritations, herpes, zona, multiple sclerosis, depression and cancers, comprising administering to a patient in need thereof an effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt, hydrate or solvate of said compound.
